Navigation Links
Pharmacyclics Files Registration Statement for Rights Offering
Date:6/1/2009

cription privilege is subject to (i) the availability and allocation of shares among holders exercising this oversubscription privilege and (ii) a maximum number of shares for which stockholders can oversubscribe without endangering the availability of the Company's net operating loss carry forwards under Section 382 of the Internal Revenue Code (the "NOLs"), in each case as further described in the rights offering documents.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The rights will be issued to all shareholders as of a record date which has yet to be determined. The exercise price of the shares also has yet to be determined. We will provide notice of the record date and exercise price in the future at such time as it is determined. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in cl
'/>"/>

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
2. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
3. Pharmacyclics Secures $5.0 Million in Debt Financing
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
6. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
7. Pharmacyclics Announces It Received Nasdaq Notification
8. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
9. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
10. Poniard Pharmaceuticals Files Shelf Registration
11. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of ... of tinnitus. Patients listen to sound therapy that is ... of weeks to months, their tinnitus volume decreases. , AudioNotch ... Music and Notched White Noise. Now, AudioNotch is pleased to ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... in technology have provided people with many items ... phones with digital audio capabilities. Technology is evolving ... considered fantasy 10 years ago are now taken ... must consider and understand how technology may evolve ...
... co-authored this commentary with Michael J. Cronin, Ph.D., J.D., an ... , ,A look at the facts in the dispute over ... - and the history behind similar disputes - shows a ... will retain all of its patent rights, even if some ...
... is writing a series of articles on raising capital from investors. ... Most of the time when raising equity capital, the offering terms ... sheet . When dealing with angel investors , it ... , ,Sometimes prospective angel investors will want to negotiate the initial ...
Cached Biology Technology:Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5WARF is likely to hold on to stem cell patent rights 2WARF is likely to hold on to stem cell patent rights 3WARF is likely to hold on to stem cell patent rights 4WARF is likely to hold on to stem cell patent rights 5WARF is likely to hold on to stem cell patent rights 6WARF is likely to hold on to stem cell patent rights 7WARF is likely to hold on to stem cell patent rights 8Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... Occurring in about one per eight hundred births, Down ... frequent genetic cause of intellectual disability. It results from ... a third copy of chromosome 21 (1% of the ... his team in the Department of Genetic Medicine and ... Medicine, published in Nature , shed light on ...
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... millions of people warding off winter,s chill with blazing ... about the potential health effects of the smoke released ... Chemical Society,s (ACS,) journal, Chemical Research in Toxicology ... lungs from wood smoke may have several adverse health ...
... , An ambitious hunt by Johns Hopkins scientists for actively ... the genome, anything but static, contains numerous pesky mobile elements ... variety of physical traits and disease risks. ... as outlined in the reference human genome to raw whole-genome ...
... , This release is available in Spanish . ... acids (AGPO-3) and the onset of depressive disorders is not new ... now is the brain mechanism by which diet can condition mental ... (France) and at the Faculty of Medicine and Odontology of the ...
Cached Biology News:Johns Hopkins researchers capture jumping genes 2Scientific research reveals brain alterations linking omega 3 deficit with depression 2Scientific research reveals brain alterations linking omega 3 deficit with depression 3
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Goat polyclonal to Duffy / FY / DARC...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... a 27kDa periplasmic enzyme from E. coli ... cyclic nucleotide monophosphate (NMP) intermediates. Slower hydrolysis ... to 3-NMPs (1). RNase ONE Ribonuclease is ... can cleave a phosophodiester bond between any ...
Biology Products: